19
05-2023
VSY Biotechnology GmbH Achieved Strong Growth in Q1 2023

VSY Biotechnology GmbH is moving towards achieving its growth targets with incremental steps. The company’s General Manager, Andreas Kühnel, evaluated the impressive Q1 2023 results of the company in the following statement:

“Our net sales in the first quarter of 2023 increased by 81% compared to the same period of last year. Back in 2022, we launched one of our premium IOL products, AcrivaUD Trinova Pro C Pupil Adaptive® with Sinusoidal Vision Technology (SVT®), which reduces halo and glare. The fact that our premium IOL product segment experienced a 38% increase in net sales compared to last year is a significant indication of our success in this specific market segment.”

“As of now, our revenue for 2023 is surpassing our expectations, and we expect this trend to continue. We’re confident that we’ll exceed our target by the end of the year, just as we did in 2022. In addition to growth in the current product portfolio, we are excited about the new products in our pipeline. We are fully focused on achieving our 5-year business plan with threefold net sales by the end of 2028.”

The financial achievement of VSY Biotechnology GmbH is a clear indication of the company’s dedication to advancing the field of ophthalmology and improving patient outcomes. With its focus on excellence in optics technology and product innovation, the company is well-positioned to achieve its growth targets and continue to lead the way in the development of premium IOL products.